Ovarian stimulation in in vitro fertilization with or without the "long" gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome

被引:7
作者
Beloosesky, R
Kol, S
Lightman, A
Itskovitz-Eldor, J
机构
[1] Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, Haifa, Israel
关键词
GnRH agonist; long protocol; controlled ovarian stimulation; IVF; stimulation duration;
D O I
10.1016/S0015-0282(00)00574-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the correlation between stimulation duration of IVF cycles, with and without GnRH agonist (GnRH-a), and cycle outcome. Design: Retrospective analysis of data. Setting: University-affiliated IVF clinic. Patient(s): 998 IVF cycles in which long GnRH-a protocol was used, and 155 cycles with hMG only. Intervention(s): IVF cycles. Main Outcome Measure(s): Cycle outcome in number of oocytes and embryos, and pregnancy rate. Result(s): The mean stimulation duration (+/-SD) was 9.6 +/- 1.7 and 6.7 +/- 1.0 for the GnRH-a and the hMG-only cycles, respectively (P<0.01). In the GnRH-a group, no statistically significant correlation between cycle duration and pregnancy rate was found. Interestingly, the patients treated for 9 days had the highest number of oocytes retrieved and the highest pregnancy rate. Stimulation duration was not affected by age in either protocol. GnRH-a cycles yielded a significantly higher number of oocytes and embryos compared to cycles without GnRH-a. The pregnancy rate was similar in both groups. Conclusion(s): Stimulation duration in the long GnRH-a protocol group was significantly longer than in the hMG-only group. Stimulation duration was not affected by age. No statistically significant correlation was found between stimulation duration and cycle outcome in the long protocol group. (Fertil Steril(R) 2000,74. 166-8. (C) 2000 by American Society for Reproductive Medicine).
引用
收藏
页码:166 / 168
页数:3
相关论文
共 4 条
[1]  
*FIVNAT, 1996, CONTRACEPT FERTIL SE, V24, P694
[2]   A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients [J].
Jansen, CAM ;
van Os, HC ;
Out, HJ ;
Bennink, HJTC .
HUMAN REPRODUCTION, 1998, 13 (11) :2995-2999
[3]  
Mannaerts B, 1998, HUM REPROD, V13, P3023
[4]  
SPEROFF L, 1999, CLIN GYNECOLOGIC END, P1112